Exploring resistance mechanism and vulnerabilities in melanoma drug tolerant states

Melanoma, which results from the malignant transformation of melanocytes, is the most aggressive form of skin cancer, primarily due to its rapid and extensive metastatic ability. Although recent advances in targeted therapy and immunotherapy have revolutionized the overall treatment landscape, the emergence of drug resistance still poses a significant challenge to achieve long-term efficacy. To this end, a comprehensive understanding of the biological mechanisms that drive resistance and progression in melanoma is needed. The primary objective of this study aimed to identify mechanisms driving drug tolerance in the context of BRAF inhibition. Using CRISPR/Cas9 screening and transcriptomic analysis, we present an unexpected role of NRF2 in mediating transcriptional and metabolic changes in melanoma cells that contribute to a drug-tolerant (DT) phenotype that resists inhibition of the MAPK pathway. Firstly, our studies uncovered that DT states are associated with a decreased activity of NRF2 and are likely the cause of the increased sensitivity of these states to ferroptosis inducing strategies. Similarly, reactivation of the NRF2 program in DTs reverted the ferroptosis-sensitive phenotype. In addition, the research shows that NRF2 activation enhances tolerance to BRAF inhibitors and alters the expression of genes implicated in the invasive state in melanoma cells, suggesting a complex interaction between NRF2 and resistance to targeted therapy. These results provide new insights into the adaptability of melanoma cells to therapeutic pressure and highlight the potential of NRF2 as a target for innovative treatments that could overcome drug tolerance and increase susceptibility to cell death. The identification of metabolic and transcriptional changes associated with the DT state also provides opportunities to develop targeted interventions to improve therapeutic outcomes. This work not only deepens our understanding of the complex response of melanoma to targeted therapies, but also highlights critical pathways that could be exploited to develop more effective and durable treatment strategies. Future research should explore the clinical application of these findings, optimize therapeutic combinations, and investigate NRF2 inhibiting strategies as a means to enhance the efficacy of treatments currently used for melanoma treatment.